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Abstract
Background: This multi-country prospective study of infants aged <1 year aims to assess the frequency of influenza
virus and respiratory syncytial virus (RSV) infections associated with hospitalizations, to describe clinical features and
antibody response to infection, and to examine predictors of very severe disease requiring intensive care.
Methods/Design: We are enrolling a hospital-based cohort and a sample of non-ill infants in four countries (Albania,
Jordan, Nicaragua, and the Philippines) using a common protocol. We are currently starting year 2 of a 2- to 3-year
study and will enroll approximately 3,000 infants hospitalized for any acute illness (respiratory or non-respiratory) during
periods of local influenza and/or RSV circulation. After informed consent and within 24 h of admission, we collect
blood and respiratory specimens and conduct an interview to assess socio-demographic characteristics, medical
history, and symptoms of acute illness (onset ≤10 days). Vital signs, interventions, and medications are documented
daily through medical record abstraction. A follow-up health assessment and collection of convalescent blood occurs
3-5 weeks after enrollment. Influenza and RSV infection is confirmed by singleplex real time reverse transcriptase
polymerase chain reaction (rRT-PCR) assays. Serologic conversion will be assessed comparing acute and convalescent
sera using hemagglutination inhibition assay for influenza antibodies and enzyme-linked immunosorbent assay (ELISA)
for RSV. Concurrent with hospital-based enrollment, respiratory specimens are also being collected (and tested by
rRT-PCR) from approximately 1,400 non-ill infants aged <1 year during routine medical or preventive care.
Discussion: The Influenza and RSV in Infants Study (IRIS) promises to expand our knowledge of the frequency,
clinical features, and antibody profiles of serious influenza and RSV disease among infants aged <1 year, quantify
the proportion of infections that may be missed by traditional surveillance, and inform decisions about the
potential value of existing and new vaccines and other prevention and treatment strategies.
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Background
International rates of hospitalization due to acute upper
and lower respiratory disease are highest among infants
aged <1 year old [1–3]. Influenza virus [1, 2, 4–6] and
respiratory syncytial virus (RSV) [7, 8] infections are
recognized as leading contributors to this burden; yet,
existing studies typically underestimate the frequency
of severe influenza and RSV diseases that require
hospitalization among infants for multiple reasons.
First, clinical complications from influenza virus infec-
tions, such as pneumonia and bronchiolitis, often occur
days after the primary infection when molecular diag-
nostics may be less sensitive to detect reduced virus
shedding by the time of hospitalization.1 However, as
demonstrated by a study in Thailand, serologic diagnos-
tics may be able to detect antibody seroconversion fol-
lowing influenza infection even among hospitalized
pneumonia patients who test negative for influenza
using molecular diagnostics [9–11]. Likewise, serology
may be a complementary tool to molecular diagnostics
in determining recent RSV infections [12, 13].
Second, existing surveillance platforms often overlook
non-febrile infections and non-respiratory manifesta-
tions of influenza and RSV infection [14–17]. For ex-
ample, in a study of children aged <3 years presenting
with fever to emergency departments in France, about 1
in 3 children with laboratory-confirmed influenza pre-
sented with a non-respiratory disease (including febrile
seizures, sepsis-like syndrome, and gastroenteritis) [14].
Likewise, RSV is typically considered an etiologic agent
in respiratory tract infections during the RSV season
[18, 19], but it is also an important cause of apnea in
preterm infants [20–22] and can present with shock
and as a sepsis-like syndrome in young infants [23–25].
Additionally, both influenza and RSV infections often
presents without fever in infants [7, 17, 26]. Thus, the true
burden and clinical manifestations of both influenza and
RSV among infants might be under-represented if subjects
are selected for pathogen testing among those with only
respiratory symptoms or only fever. Finally, confidence
in the etiologic role of influenza and RSV in infant
hospitalization requires comparative information on the
prevalence of these infections among non-ill infants at
the same time and from the same communities, which
is often overlooked in epidemiologic studies of this
population [27].
This U.S. Centers for Disease Control and Prevention
(US CDC) funded multi-site prospective study will enroll
approximately 3,000 infants aged <1 year hospitalized
for any acute illness and a comparison sample of
approximately 1,400 non-ill infants.2 Here we provide an
overview of the design and methods of the Influenza
and RSV in Infants Study (IRIS) currently starting year 2
of a 2- to 3-year study in Albania, Jordan, Nicaragua,
and the Philippines. Our study aims are to assess the fre-
quency of influenza- and RSV-associated hospitalizations
(i.e., severe disease) for respiratory and non-respiratory
diseases, describe the clinical features of these infections
and the predictors of intensive care (i.e., very severe dis-
ease), and describe the antibody response to influenza
virus and RSV infections. Table 1 lists the knowledge
gaps we identified within each of these aims and the
study features intended to address these gaps.
Methods/Design
This prospective study consists of a hospital-based
cohort and a cross-sectional sample of non-ill infants
enrolled over 3 years in hospitals and ambulatory care
settings serving infants in four countries (Table 2).3 All
study sites use a common protocol and data collection
tools (using personal computers or mobile devices).4
The design and screening methodologies for the hospital
and community studies are described separately (below)
followed by a description of common laboratory, statis-
tical, and data management procedures.
Hospitalized infants study design
For each study year, each site is enrolling approximately
350–500 infants aged <1 year old hospitalized with an
acute medical illness during periods of local influenza
circulation in year 1 and during periods of either influ-
enza viruses or RSV circulation starting in year 2 (and
for any subsequent years of the study), as indicated by
local and national virus surveillance platforms.5 We in-
tend to begin enrollment during the early phase of local
influenza virus and RSV circulation and continue past
the peak through the decline in local circulation if pos-
sible. Enrollment goals are set per week in order to sam-
ple infants and extend the use of resources across the
study period; enrollment can potentially expand during
periods of peak circulation of either influenza or RSV.6
Each day, study staff use hospital admission records
(including presenting complaints and preliminary admis-
sion diagnoses) to register all acutely ill infants and strat-
ify them into respiratory versus non-respiratory illness
groups and general ward versus intensive care unit
(ICU) placements (Fig. 1).7 Infants within the resulting
four strata are randomly sorted and prioritized in order
to approach a mixture of patient types until the max-
imum daily enrollment in each group has been met. 8
Infants are screened for eligibility within 24 h of hospital
admission to confirm that the family lives in the local
area and that the illness onset was within the prior
10 days. Only basic descriptive information is then
recorded for infants who are ineligible, are not
approached, or whose parents refuse informed consent;
these data will be used to assess possible selection bias
and to describe the denominator of weekly hospitalized
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acutely ill infants. Study staff collect other hospital cen-
sus information daily, including the number of available
pediatric general ward and ICU beds, to consider differ-
ences in access to hospital care over time and between
study sites.
After completing written informed consent, extensive
socio-demographic [28, 29], epidemiological, and clin-
ical information is collected at enrollment, at a 3–5
week follow-up encounter, and through hospital record
abstraction (summarized in Table 3). Respiratory speci-
mens using combined nasal and oropharyngeal (OP)
swabs (or endotracheal aspirate for intubated infants) and
up to 2.5 ml of blood are collected by trained staff within
24 h of admission.9 Information on socio-demographic
characteristics, medical history, maternal and infant
vaccination history (documented from vaccination cards
when available), and symptoms of the acute illness are
gathered from parents (or guardians).
Hospital records are abstracted to document clinical
signs and measurements at admission, including clinician-
measured temperature, respiration rate, and oxygen
saturation. For each subsequent day of hospitalization, we
Table 1 Study goals and features intended to address specific
knowledge gaps
A. Assess the frequency of influenza- and RSV-associated hospitalizations
among infants ages <1 year old
Knowledge Gap Study Feature




Enroll patients in study sites
located in four diverse middle-
income countries (Albania, Jordan,
Nicaragua, and The Philippines).
Studies often enroll only
during peak periods of
virus circulation.
Enroll patients during an extended
period to take into account prolonged
and overlapping periods of influenza
and RSV circulation.
Typical severe acute respiratory
illness (SARI) surveillance
strategies use highly specific
case definitions that overlook
non-respiratory and non-febrile
manifestations of disease.
Enroll admissions due to any acute
(respiratory and non-respiratory)
illnesses; describe the clinical




often occur after acute viral
infections, and thus viral
shedding may be missed by
the time of hospitalization.
In addition to molecular diagnostics,
serologic assays will be used to
identify recent influenza and RSV
infections.
More information is needed
on the virus-specific
attributable fraction for
influenza and RSV disease.
Assess the prevalence of influenza
and RSV infections among healthy
infants who have not been ill for at
least 7 days at specimen collection
(all study years) and confirm absence
of symptoms up to 4–10 days after
collection (starting in year 2 and
continuing afterwards).
B. Describe the clinical features of influenza- and RSV-associated
hospitalizations among infants and the predictors of very severe
disease
Knowledge Gap Study Feature
Information is limited on the
non-respiratory disease
manifestations of influenza
and RSV infections among
infants.
Assess the frequency of influenza
and RSV infections among infants
hospitalized with non-respiratory
illness (including febrile seizures,
otitis media, diarrhea,
and sepsis-like syndromes).
The range of clinical severity
for influenza and RSV
infections among infants is
poorly characterized outside
of high-income countries.
Examine symptoms and signs
(including temperature, oxygen
saturation, and respiration), oxygen
support, and treatments at
admission and then daily during
hospitalization for influenza and RSV
infected infants.
Extent to which antibiotics may
be over-utilized and influenza
antivirals may be under-utilized
among infants is unclear,
especially outside of
high-income countries.
Describe the use of and timing of
administration of antibacterial and
antiviral agents during infants’
hospitalization.
Further research is needed
to identify risk factors for very




Assess the characteristics of infants
(e.g., age, sex, prematurity, co-morbid
conditions), viruses, and environmental
characteristics (e.g., socio-economic status,
household composition, distance
from hospital) associated with more
severe illness presentation.
Table 1 Study goals and features intended to address specific
knowledge gaps (Continued)
Information on the clinical
course of influenza and RSV
infections during and
following hospitalization is
limited, especially outside of
high-income countries.
Describe the length of stay in the
general ward or ICU and the frequency
of death and hospital re-admission
within 30 days post-discharge among
enrolled infants.
C. Describe the acute antibodies to influenza and RSV by months of age
among infants <1 year old and their humoral immune response to
infections.
Knowledge Gap Study Feature
Given that infancy is a period
of dynamic immune system
development, there is limited
information on the antibody
response of infants.
Describe the influenza and RSV
antibody response of infants by age
sub-strata for all infants at hospital
admission.
More information is needed
on the prevalence of influenza




In study sites where influenza
vaccination is available, describe the
influenza antibody profiles of infants
born to influenza vaccinated vs.
unvaccinated mothers.
Implications of pre-infection
influenza and RSV antibodies
to the manifestation of disease
and immune response among
infants are unclear (especially
those aged <6 months).
Compare acute antibodies for influenza
and RSV (at hospital admission) and
subsequent sero-conversion among
infants receiving general vs. intensive
care by age sub-strata.
Information on the frequency
with which influenza and RSV
infections result in robust
antibody response is limited,
especially by sub-age-strata
among infants aged <1 year.
Describe the frequency of serologic
conversion to influenza and RSV using
acute and convalescent sera among
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Sponsoring Institution Hospitalized Infant Study Non-Ill Infant Study











South East European Center






88 25 Enrolled during well-baby immunization
visits to (a) Mother and Child Consultancy
Room, Health Center No. 4 Tirana, Tirana
Regional Health Authority, and (b) the
Pediatric Surgical Ward, University











120 70 Enrolled from Al-Owdah Primary
Healthcare Center, which provides
maternal and child health services; infants
are recruited during routine visits for





Sustainable Sciences Institute Hospital Infantil
Manual De Jesus
Rivera “La Mascota”
270 31 Enrolled from Health Center Socrates
Flores Vivas during immunization visits,
well-baby check-ups, and from a local










42 8 Enrolled during immunization visits at (a)
Cogon Lower Barangay Health Station, (b)
Cogon Upper Barangay Health Station,
and (c) Taloto Health Center
Fig. 1 Steps in Hospital Enrollment and Follow-up
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Table 3 Key Variables and Sources of Information for Hospitalized and Non-Ill Infants





Combined nasal and oropharyngeal swabs √ √
Blood (Sera) √ √
Endotracheal aspirate (for intubated infants) √
Infant illness
Date of illness onset and resolution √ √
Maternal-reported symptoms √ √
Ambulatory and self-care for illness √ √
Clinical signs at admission and per day √
Clinical diagnoses √
Clinical interventions √
Clinical laboratory results √
Clinical radiographic information √
Readmission to hospital √ √
Other hospitalizations post-discharge √ √
Infant characteristics
Demographic (sex, birth date, race, ethnicity) information √ √
Current weight √ √ √ √
Current length √ √ √ √
Perceived overall health and functioning √ √ √
Influenza vaccination status (from vaccination cards when available) √ √ √ √
Delivery characteristics (including gestational age, birth weight,
complications and abnormalities)
√ √ √
Diagnoses and history of care for chronic conditions √ √ √
Diagnoses and history of care for prior acute illnesses √ √ √
Results of previous laboratory tests √
Other immunization status √ √ √ √
Daycare attendance √ √
Household characteristics
Age of each household member √ √
Education and occupation of parents (or guardians) √ √
House size and number of rooms √ √
Subjective social status √ √
Household wealth index √ √
Household smoking √ √
Maternal characteristics
Subjective health status √ √ √
Medical conditions √ √
Pregnancy history and complications during study infant’s gestation √ √
History of and current breastfeeding √ √
Influenza vaccination status (from vaccination cards when available) √ √ √ √
Knowledge of and worry about influenza illness √ √
Knowledge of and attitudes toward influenza vaccine for infants aged ≥6 months √ √
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document clinical signs and the lowest and highest mea-
surements of vital signs and oxygen saturation. Clinical
diagnoses at admission and discharge are recorded,
including International Classification of Diseases (ICD)
codes for discharge diagnoses. Clinical interventions,
such as oxygen support, and treatments (including anti-
bacterial and antiviral agents) are documented through-
out hospitalization. Clinical laboratory values (such as
white blood cell count) and test results (including bac-
terial, viral, and parasite detection), chest radiographic
information (including digital images, if available), and
other clinical assessments carried out as part of regular
clinical care are also recorded. We also document
hospital readmissions within 30 days of discharge for
the index illness.
All infants in the hospital-based cohort complete a
follow-up assessment and a convalescent blood draw
(up to 2.5 ml of blood) 3–5 weeks after enrollment
through hospital or home visits. Information on the
infant’s health since hospital discharge (including
recovery, readmission, or death) are gathered from
parents and may be supplemented by review of medical
and administrative records. At the follow-up assess-
ment, questions about knowledge, attitudes, and prac-
tices (KAP) toward influenza illness, including the
extent of worry about influenza [30], are asked for all
parents; KAP toward influenza vaccines are asked
among parents of infants aged >6 months, including
previously validated measures of intention to vaccinate
[31–33] and the perceived effectiveness and safety of
influenza vaccines [31, 33].
Community non-ill infants study design
For each study year, concurrent with hospital enroll-
ment, approximately 150–300 non-ill infants aged
<1 year per site are enrolled during routine preventive
care encounters with weekly enrollment goals stratified
by ages 0–5 months and 6–11 months in order to re-
flect the mixture of ages observed among hospitalized
infants. As described in Table 2, all study sites enrolled
non-ill infants during routine immunization visits; Jordan
also enrolled infants during routine growth monitoring
and other well-baby check-up visits; Nicaragua enrolled
additional non-ill infants from an existing prospective co-
hort study [34, 35]. Screening questions confirm that the
infant has not been acutely ill within the past 7 days with
nasal congestion or discharge, new or worsening cough,
shortness of breath, difficulty breathing, wheezing, fever,
chills, or diarrhea. After informed consent is obtained
from parents, trained staff collect combined nasal and OP
swabs and complete a structured interview covering the
same infant, household, maternal characteristics, and KAP
assessed for hospitalized infants (Table 3). No blood is
collected from non-ill infants. Starting in the second year
of the study, a follow-up contact will be made to parents
of non-ill infants (4–10 days after enrollment) to assess
whether the infant developed illness symptoms after the
initial interview.
Laboratory methods
Respiratory specimens are tested for influenza and RSV
by reference laboratories at each study site using
validated singleplex real time reverse transcriptase poly-
merase chain reaction (rRT-PCR) assays, with proto-
cols, primers, probes, and reagents supplied by US
CDC.10 Study laboratories completed WHO influenza
proficiency panels and quality assurance testing (of
every 5th influenza positive and every 20th influenza
negative) administered by Marshfield Clinic Laboratory
(Marshfield, Wisconsin). RSV proficiency panels were
administered and reviewed by US CDC.
Also at each study site’s research laboratory, we will
complete multiple virus testing on respiratory speci-
mens from both hospitalized and non-ill infants using
multiplex real-time PCR for detection of pathogen
genes by TaqMan® technology (Fast-track Diagnostics
[FTD], Silema, Malta); specifically, we are utilizing
FTD Respiratory Pathogens 21, which is a five tube
multiplex for detection of influenza A virus, influenza
A(H1N1) swine virus, influenza B virus, rhinoviruses,
coronaviruses (NL63, 229E, OC43, HKU1), parainflu-
enza viruses 1-4, human metapneumovirus, bocavirus,
respiratory syncytial virus, adenoviruses, enteroviruses,
parechoviruses, Mycoplasma pneumoniae, and an in-
ternal control. Prior to beginning multiplex testing,
each site laboratory completed Respiratory II EQA
(External Quality Assessment) Programme by QCMD
(Glasgow, Scotland; RESPII16 Catalogue Number
QAV164189), which includes molecular detection and
determination of human metapneumovirus, respiratory
adenoviruses, rhinoviruses, coronaviruses and para-
influenza viruses. Although we will compare influenza
and RSV results from both singleplex and multiplex as-
says, the singleplex rRT-PCR results will be the “gold
standard” or primary assay.
A random subset of all influenza viruses may undergo
virus isolation, depending on the availability of virus
characterization information from local surveillance
platforms. Also, some influenza viruses/specimens may
have molecular characterization with genetic sequencing
and other assays to detect genetic markers and antiviral
resistance. A sampling of specimens positive for RSV
will be selected and characterized by target genetic se-
quencing. Remaining aliquots of all study respiratory
specimens will be sent to a CDC-designated facility for
banking and storage; no specimens will contain personal
identifiers. These specimens may also be utilized to
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investigate biomarkers of disease severity or novel vi-
ruses or pathogens.
Hemagglutination inhibition (HI) assay will be com-
pleted following the US CDC protocol [36] at the
Battelle laboratory (Aberdeen, Maryland), after com-
pleting a proficiency panel. Duplicate results will be
used to calculate the geometric mean antibody titer
(GMT) against seven influenza A and B virus strains
that include local influenza vaccine strains and circu-
lating strains for the study year (for possible infant
exposure) and prior years (for possible maternal ex-
posure). Serologic confirmation of influenza infection
will be defined as ≥4 fold rise in GMT from acute to
convalescent sera, with convalescent HI titer of ≥ 40
GMT.
RSV-specific serum IgG, IgM, and IgA will be detected
using standard enzyme-linked immunosorbent assay
(ELISA) procedures [37, 38]. Endpoint titers will be de-
termined for serum antibodies to the F and G proteins
of RSV.
Data management
Data collection and site-level management are con-
ducted using REDCap (Research Electronic Data
Capture), which is a browser-based metadata-driven
software system (Vanderbilt University, Nashville, TN)
[39]. The recruitment log (including randomization and
prioritization by recruitment strata), screening survey,
informed consent, enrollment interview, specimen
management, laboratory tracking and results, daily hos-
pital abstraction, and follow-up assessment occur via
REDCap forms on personal computers or mobile de-
vices (tablets or smart phones).
Routine quality assurance monitoring is conducted
at each study site and centrally by the data coordin-
ator (Abt Associates). Missing or unclear information
is corrected through follow-up contact with parents
or medical record abstraction. Chained imputation
methods or other methods will be used for imputing
missing covariate data (i.e., not primary outcomes), if
necessary.
Statistical considerations
Sample needs for the objectives to assess the percent-
age of influenza and/or RSV positives (by molecular or
serologic methods) are driven by the precision with
which we wish to measure the lowest expected per-
centage of infection for a particular category of infant
hospitalizations at a specific study site. For optimum
precision, we intend that the 95% confidence interval
(CI) is within the range of plus or minus 50% of the
observed percentage positive. For example, in order to
measure a percentage of rRT-PCR confirmed influenza of
5% (with a 95% CI from 2.5–7.5%) within a particular
patient strata would require a sample size of 328 (and
16 positives) [40]. Thus, we expect to make site-specific
estimates for large infant categories (e.g., respiratory vs.
non-respiratory illnesses). However, it will be necessary
to combine results across study sites in order to estimate
positivity for combinations of categories (e.g., non-
respiratory illnesses among infants aged 0–5 months in
ICU).
Sample goals for the non-ill infants were originally
made with the expectation of observing at least 2% of in-
fants positive for influenza virus and RSV infections [27,
41–43]. We recognized that 200 non-ill infants would be
needed to observe a 2% rate of virus positivity with
minimum precision (with a 95% CI = +/- 1.9%).
Estimation of the attributable fraction of disease asso-
ciated with influenza or RSV will require statistical ad-
justment and/or matching of ill and non-ill infants by
season, weeks within season, age, and characteristics
that may differ between infants recruited from pre-
ventive care settings and the source population [27].
The proposed 150–300 non-ill enrollees per year may
not be adequate to capture this variation adequately.
Ethical approval & ethical considerations
The study protocol and procedures have been reviewed
and approved by Institutional Review Boards (IRBs) at
each study site and by Abt Associates (the coordinating
institution on which US CDC relies). Written informed
consent is completed in the parent or guardian’s lan-
guage (Spanish, Arabic, Albanian, or Visayan [Boholano
dialect]).11 Provision of a small gift or travel reimburse-
ment vary by study site depending on local IRB guidelines.
Whenever possible, blood collection is coordinated with
clinically necessary blood draws. Given the research na-
ture of the laboratory methods and time delays in batch
testing, rRT-PCR findings are not available to inform clin-
ical decisions.
Discussion
We described the recruitment, data gathering, labora-
tory, and follow-up procedures for this prospective study
of approximately 3,000 hospitalized infants and 1,400
non-ill infants aged <1 year as part of the US CDC-
funded IRIS network. Estimating the hospital burden of
severe infant disease associated with influenza and RSV
and expanding our understanding of the clinical presen-
tation and antibody response associated with these dis-
eases are especially timely and relevant aims given
existing and new immunoprophylaxis options for RSV
[44, 45], the existing availability of influenza vaccines,
and the development of new types of influenza and RSV
vaccines and vaccine strategies to provide direct or indir-
ect protection for infants [46–49].
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Study strengths
By focusing on all acute infant illnesses, our prospective
study promises to quantify the proportion of severe in-
fluenza and RSV disease that is missed by traditional
surveillance approaches, case definitions, and molecular
diagnostics. It is unique in its systematic sampling of
acutely ill infants that does not rely on clinical judgment,
its collection of in-depth clinical and socio-demographic
information, and its use of both molecular and sero-
logic diagnostics. Our Network extends research be-
yond the USA and other high-income countries and
also includes countries with prolonged or multiple
epidemic periods (Nicaragua and the Philippines),
which are also under-represented in influenza and
RSV research. Other strengths include the multi-
country composition of our network, which will allow
us to examine the consistency of trends across settings
with different medical systems and infant populations.
In addition, given the multi-agent source of many
infant diseases [27, 50–55] and the absence of com-
munity controls in many hospital studies [27], the en-
rollment of non-ill infants from the same community
is an important study feature which will allow us to
examine the frequency of influenza virus and RSV
infections among non-ill infants and, depending on
sample size and virus attack rate, possibly estimate the
virus-specific attributable fraction of influenza and
RSV to severe disease.
Limitations
Our study has at least six limitations. First, the number
and types of influenza virus infections we identify will
depend on the circulating viruses in each country during
the years of our study and may under- or over-estimate
the expected frequency of disease in future years. In-
deed, reviews of influenza studies in Africa and India ob-
served 5- to 20-fold differences in incidence estimates
across studies [56, 57]. Similarly, due to the timing and
funding cycle of the study, we may not enroll infants
during complete influenza and RSV seasons in all coun-
tries for all study years.
Second, different hospitals and medical systems likely
have different clinical thresholds for hospitalization
[6, 27, 58, 59], which will make comparisons across set-
tings difficult; yet, this may be less of a concern when we
examine the subset of infants requiring intensive care,
who would likely be admitted in most settings. Third, the
IRIS network does not include a low income country.
Therefore, our ability to generalize from the middle-
income countries in the IRIS network to low-income
countries, where the burden of infant disease is high and
access to hospital care is poor, is limited.
Fourth, although we expect our study methods will in-
crease the identification of influenza and RSV infections,
we recognize that our observations will continue to
underestimate the true burden of these diseases; for ex-
ample, serologic diagnostic assays will fail to identify
some infections due to known limits in the measure-
ment sensitivity of HI [60–62] and the inability of im-
mune challenged infants to mount a robust antibody
response [63–65]. Fifth, as an observational study that
relies on existing local clinical practices, we will not have
standardized measures of vital signs or clinical labora-
tory values using common procedures and calibrated in-
struments, which will limit the validity, reliability, and
comparability of these indicators. Sixth, our focus on
viral etiologies excludes description of other infectious
and non-infectious etiologies of acute illness.
Conclusions
The IRIS network promises to expand our knowledge of
the frequency, clinical features, and antibody responses
associated with serious influenza and RSV disease
among infants aged <1 year. Although variations in find-
ings across study sites and years is a common challenge
[66], we hope to identify at least two consistent trends
regarding influenza among infants: (i) the proportion of
non-respiratory hospital admissions among infants that
are associated with influenza infections; (ii) the propor-
tion of influenza infections that are missed by molecular
diagnostics but can be identified by serologic diagnostics.
For RSV, we aim to: (iii) identify risk factors associated
with severe RSV disease across countries; (iv) evaluate
the RSV-specific antibody response among infants hospi-
talized with severe RSV infections. These insights could
aid countries in making more precise estimates of dis-
ease burden and inform decisions about the potential
value of existing and new vaccines and other prevention
and treatment strategies.
Endnotes
1The duration of viral shedding among infants may be
less of a concern for RSV infections, where prolonged
viral shedding has been observed in studies of symptom-
atic children (Munywoki, et al. [67]).
2Study planning began at a workshop on April 15–16,
2015 in Atlanta, Georgia USA attended by site principal
and co-investigators and investigators and advisors from
US CDC and Abt Associates. A second planning work-
shop by investigators to review results of the first year of
enrollment and make minor revisions to protocols
and procedures took place in Tirana, Albania on
April 25–28, 2016.
3All sites have completed year 1 enrollment within the
following enrollment dates: Nicaragua (6/26/2015–1/29/
2016), Philippines (10/1/2015–9/30/2016), Albania (12/
1/2015–5/2/2016), and Jordan (12/27/2015–5/2/2016).
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4The Philippines site changed their primary enroll-
ment sites during several months in 2016 in the
following ways. During June to September, 2016, the
Philippines site attempted to expand enrollment of hos-
pitalized infants at four small hospitals on Bohol Island
(Borja Family Hospital, Ramiro Community Hospital,
Tagbilaran Community Hospital, and Tagbilaran
Maternity & Children’s Hospital). Given the relatively
small number of eligible infants hospitalized in these
settings, the site returned to enrolling infants only
from the primary hospital (Governor Celestino Gallares
Memorial Regional Hospital) starting in October, 2016.
Also, during the initial months of the study (October to
December, 2015), the site attempted to enroll non-acutely
ill infants scheduled for routine surgical procedures at the
primary study hospital, but abandoned this approach due
to the relatively small number of eligible non-ill infants
that could be enrolled from this setting.
5Specifically, Albania plans to enroll during November
through May for each study season based on historical
patterns of seasonal influenza circulation as documented
by national sentinel surveillance systems for Severe
Acute Respiratory Illness (SARI) and Influenza-like Ill-
ness (ILI) at the Institute of Public Health. Jordan plans
to enroll during December through April for each study
season, with the start of enrollment also informed by re-
ports of rRT-PCR confirmed influenza cases from the
Central Public Health Laboratory of Jordan through
their sentinel surveillance networks. Nicaragua enrolled
from June through February in the first year, based on
historical influenza data from two ongoing pediatric co-
hort studies in Managua, previously described (Gordon,
2015; Gresh, 2016); starting in year 2, enrollment began
a month earlier, based on historical surveillance data
that indicated RSV circulation began as early as May.
The Philippines plans to continue enrollment in year 1
through December, 2016, based on indicators of multiple
influenza epidemic periods as documented by WHO
FluNet surveillance; additional data on influenza and
RSV circulation was referenced from the National Influ-
enza Center at the Research Institute for Tropical Medi-
cine in Manilla.
6For example, Nicaragua implement a three-tiered en-
rollment plan in year 1 whereby enrollment increased
when either (1) >5% of cohort samples are influenza
positive or (2) 5% of national surveillance samples from
Managua are influenza positive. Enrollment targets
ranged from 4–24 hospitalized infants per week and 0 to
12 non-ill infants per week. Enrollment decreased one
week following influenza positivity rates dropping below
5% among samples from the community cohort, national
surveillance platforms, and study hospital. In year 2, en-
rollment will increase when either (1) >5% of cohort
samples are influenza positive, (2) >5% of national
surveillance samples are influenza positive, (3) >5% of
study samples are influenza positive, or (4) >10% of
study samples are RSV positive. Enrollment targets will
range from 6–28 hospitalized infants per week and 3–11
non-ill infants per week. Enrollment will decrease when
none of the preceding conditions are met.
7Exclusion criteria including (a) Residence is outside
of local area and thus unable to participate in follow-up;
(b) Parent or guardian is not available to provide infor-
mation on the infant’s index illness or medical history;
(c) Parent or guardian is unable to understand informed
consent due to language or other communication bar-
rier; (d) Infant is presenting for a non-acute illness such
as injuries, congenital ailments, or chronic conditions
(without an acute onset date); (e) Infant has not been
discharged from the hospital after delivery.
8Specific clinical admission diagnoses monitored by all
sites include respiratory illnesses (e.g., acute respiratory
distress syndrome, asthma exacerbation, bronchiolitis,
pertussis-like syndrome, pneumonia, reactive airway
disease exacerbation, respiratory failure) and non-
respiratory illnesses (e.g., bacteremia, dehydration, en-
cephalitis, febrile seizures, meningitis, sepsis, urinary
tract infection). At admission, these are preliminary
clinical diagnoses or symptom and syndromic descrip-
tions; they are not captured as ICD codes at study sites
during the period when enrollment occurs. Acute ill-
nesses can be categorized as involving respiratory only,
non-respiratory only, or both respiratory and non-
respiratory presentations. For the purposes of stratifica-
tion and sampling, infants with both respiratory and
non-respiratory illness indications are counted in the
respiratory category. In this way, we prioritize enroll-
ment of infants with non-respiratory presentations
given the importance of enrolling infants with atypical
influenza or RSV disease. This initial categorization
only serves to prioritize screening; complete signs,
symptoms, and diagnoses are recorded for all enrolled
infants.
9Nasal and oropharyngeal swabs are ULT Minitip flock
swabs (Copan Diagnostics, Inc., Murrieta, CA USA).
After collection, they will be combined in the same tube
with MicroTest Room Temperature transport medium
from Remel Products (Lenexa, KS USA).
10Site laboratories are Institute of Public Health Tirana
(Albania), Central Public Health Laboratory Jordan,
Centro Nacional de Diagnostico y Referencia (CNDR)
(Nicaragua), and Research Institute for Tropic Medicine
(Philippines). All laboratories are WHO National Influ-
enza Centers.
11English translations of the informed consent docu-
ments from each study site, approved by Institutional
Review Boards at study sites and at Abt Associates, are
available from the authors.
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